# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Finding useful health information on the Internet can be difficult, but we’re here to help. This page gathers quality information from trusted sources. You can learn more about the disease, visit handpicked websites, and find resources to help you in your daily life. Need more information? Click the menu on the left to find more!

 

B-Cell Lymphomas

Get Update

Clinical Trials

This information is provided by ClinicalTrials.gov

Search Clinical Trials
Displaying 491-500 of 562 results.
A Safety and Pharmacokinetic Study of IGM-2323 in Subjects With Relapsed/Refractory Non-Hodgkin Lymphoma
Status: Recruiting
Last Changed: Feb 21, 2020
First Received: Sep 10, 2019
Disease(s): Non-Hodgkin Lymphoma, Follicular Lymphoma, DLBCL, Mantle Cell Lymphoma, Marginal Zone Lymphoma
Intervention(s): IGM-2323, IGM-2323
Locations: Honor Health Research Institute, Phoenix, Arizona, United States
City of Hope, Duarte, California, United States
Dana Farber Cancer Institute (DFCI), Boston, Massachusetts, United States
Tennessee Oncology, Nashville, Tennessee, United States
MD Anderson Cancer Center, Houston, Texas, United States
... and 2 other locations.
A Phase 2 Study of NIR178 in Combination With PDR001 in Patients With Solid Tumors and Non-Hodgkin Lymphoma
Status: Recruiting
Last Changed: Jun 23, 2020
First Received: Jul 05, 2017
Disease(s): NSCLC, Non Small Cell Lung Cancer, RCC, Renal Cell Cancer, Pancreatic Cancer, Urothelial Cancer, Head and Neck Cancer, DLBCL, Diffused Large B Cell Lymphoma, MSS, Microsatellite Stable Colon Cancer, TNBC, Triple Negative Breast Cancer, Melanoma, mCRPC, Metastatic Castration Resistant Prostate Cancer
Intervention(s): NIR178, PDR001
Locations: University of California, Los Angeles, Santa Monica, California, United States
H Lee Moffitt Cancer Center and Research Institute Inc, Tampa, Florida, United States
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States
The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
MD Anderson Cancer Center/University of Texas, Houston, Texas, United States
... and 17 other locations.
LITT and Pembrolizumab in Recurrent Brain Metastasis
Status: Recruiting
Last Changed: May 06, 2020
First Received: Dec 05, 2019
Disease(s): Melanoma, Non-small Cell Lung Carcinoma (NSCLC), Renal Cell Carcinoma (RCC), Small-cell Lung Cancer, Head and Neck Squamous Cell Cancer, Classical Hodgkin Lymphoma, Primary Mediastinal Large B-Cell Lymphoma, Urothelial Carcinoma, Microsatellite Instability-High Cancer, Gastric Cancer, Esophageal Cancer, Cervical Cancer, Hepatocellular Carcinoma, Merkel Cell Carcinoma, Brain Metastases, Adult
Intervention(s): LITT + Pembrolizumab
Locations: McKnight Brain Institute of the University of Florida, Gainesville, Florida, United States
Personalized NK Cell Therapy After Chemotherapy and Cord Blood Transplant in Treating Patients With Myelodysplastic Syndrome, Leukemia, Lymphoma or Multiple Myeloma
Status: Recruiting
Last Changed: Dec 16, 2019
First Received: Apr 05, 2016
Disease(s): Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Biphenotypic Leukemia, Acute Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia in Remission, Acute Myeloid Leukemia With Myelodysplasia-Related Changes, Acute Myeloid Leukemia With Variant MLL Translocations, B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, Chemotherapy-Related Leukemia, Chronic Myelomonocytic Leukemia, Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, ISS Stage II Plasma Cell Myeloma, ISS Stage III Plasma Cell Myeloma, Myelodysplastic Syndrome, Myelodysplastic Syndrome With Excess Blasts, Myelodysplastic Syndrome With Gene Mutation, Myelodysplastic/Myeloproliferative Neoplasm, Previously Treated Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia, Recurrent Adult Acute Myeloid Leukemia, Recurrent Hodgkin Lymphoma, Recurrent Non-Hodgkin Lymphoma, Refractory Acute Lymphoblastic Leukemia, Refractory Adult Acute Lymphoblastic Leukemia, Secondary Acute Myeloid Leukemia, Therapy-Related Myelodysplastic Syndrome
Intervention(s): Allogeneic Natural Killer Cell Line NK-92, Anti-Thymocyte Globulin, Busulfan, Clofarabine, Cyclophosphamide, Fludarabine Phosphate, Laboratory Biomarker Analysis, Melphalan, Rituximab, Total-Body Irradiation, Umbilical Cord Blood Transplantation
Locations: M D Anderson Cancer Center, Houston, Texas, United States
A Study to Evaluate the Safety,PK and PD of APG-2575 in Patients With Hematologic Malignancies
Status: Recruiting
Last Changed: Jul 20, 2020
First Received: Apr 12, 2019
Disease(s): Chronic Lymphocytic Leukemia, Non Hodgkin Lymphoma
Intervention(s): APG-2575
Locations: Blood Diseases Hospital Chinese Academy of Medical Sciences, Tianjin, Tianjin, China
Phase 1 Study of Ibrutinib and Immuno-Chemotherapy Using Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib,Rituximab (TEDDI-R) in Primary CNS Lymphoma
Status: Recruiting
Last Changed: Jul 30, 2020
First Received: Jul 30, 2014
Disease(s): Primary Central Nervous System Lymphoma
Intervention(s): Isavuconazole, TEDDI, Rituximab, Cytarabine, TEDD, Ibrutinib (Arms 2 and 3), Ibrutinib (Arm 1 - Closed with Amendment G)
Locations: National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
A Safety and Efficacy Trial of JCAR017 Combinations in Subjects With Relapsed/Refractory B-cell Malignancies (PLATFORM)
Status: Recruiting
Last Changed: Aug 05, 2020
First Received: Oct 16, 2017
Disease(s): Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Follicular
Intervention(s): JCAR017, Durvalumab, CC-122, Ibrutinib, CC-220
Locations: City of Hope National Medical Center, Duarte, California, United States
Northwestern University School of Medicine, Chicago, Illinois, United States
Massachusetts General Hospital, Boston, Massachusetts, United States
University of Nebraska Medical Center, Omaha, Nebraska, United States
University of Pennsylvania, Philadelphia, Pennsylvania, United States
... and 2 other locations.
Phase I Study of MIK665, a Mcl-1 Inhibitor, in Patients With Refractory or Relapsed Lymphoma or Multiple Myeloma
Status: Recruiting
Last Changed: Jun 22, 2020
First Received: Dec 14, 2016
Disease(s): Multiple Myeloma (MM), Lymphoma, Large B-Cell, Diffuse (DLBCL), Lymphoma
Intervention(s): MIK665
Locations: Ohio State University Medical Center Main Site, Columbus, Ohio, United States
MD Anderson Cancer Center/University of Texas MD Anderson CC, Houston, Texas, United States
Novartis Investigative Site, Heidelberg, Victoria, Australia
Novartis Investigative Site, Nantes Cedex 1, France
Novartis Investigative Site, Heidelberg, Germany
... and 5 other locations.
A Clinical Trial of Metformin in the Maintenance of Non-Hodgkin's Lymphoma Patients
Status: Recruiting
Last Changed: Mar 11, 2020
First Received: Jul 26, 2018
Disease(s): Lymphoma, Large B-Cell, Diffuse, Stage III Follicular Lymphoma
Intervention(s): Metformin, Placebos
Locations: Ruijin Hospital, Shanghai, China
EPOCH and Rituximab to Treat Non-Hodgkin's Lymphoma in Patients With HIV Infection
Status: Recruiting
Last Changed: Jul 17, 2020
First Received: Nov 06, 2000
Disease(s): Lymphoma, AIDS-related, Lymphoma, Large B-Cell, Diffuse
Intervention(s): Rituximab, filgrastim, EPOCH
Locations: National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States